Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Efficacy of cerebroxin capsules combined with aspirin in prevention of post-ischemic stroke in patients treated with thrombolysis

Jiaqi Wang, Hong Tan

Department of Neurology, Changsha First Hospital, Changsha, China;

For correspondence:- Hong Tan Email: tanh68@126.com Tel:+8673184667660

Accepted: 6 February 2024 Published: 29 February 2024

Citation: Wang J, Tan H. Efficacy of cerebroxin capsules combined with aspirin in prevention of post-ischemic stroke in patients treated with thrombolysis. Trop J Pharm Res 2024; 23(2):415-421 doi: 10.4314/tjpr.v23i2.23

© 2024 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To analyze the efficacy of Cerebro-Cardiac capsules combined with aspirin for secondary prevention in post-ischemic stroke patients treated with thrombolysis, and also to explore its clinical application value.

Methods: 224 ischemic stroke patients in the outpatient clinic of Changsha First Hospital, China from June 2022 to December 2022 were randomly divided into treatment and control groups, with 112 patients per group. Both groups were given oral aspirin (100 mg/daily) but treatment group received cerebroxin capsules (four capsules, three times daily) in addition. The types of recurrent strokes, clinical efficacy, NIHSS score scale, modified Barthel index, levels of fibrinogen and plasma viscosity, total cholesterol and triacylglycerol were assessed and compared between the groups.

Results: During the 6-month follow-up, 10 patients in treatment group and 12 patients in control group experienced dislodgment, and 202 cases completed treatment, but the difference was not statistically significant (p > 0.05). Treatment group showed a higher effective rate (92 %) compared to control group (75 %), with a statistically significant difference in clinical symptom efficacy (p < 0.05). Hemodynamic parameters were significantly better in treatment group than in control group (p < 0.05). Both groups exhibited improved total cholesterol levels, triacylglycerol levels and modified Barthel index post-treatment. Treatment group had better NIHSS scores and Barthel index than control group (p < 0.05), while their triacylglycerol levels were lower (p < 0.05).

Conclusions: Cerebroxin capsules combined with aspirin improve the symptomatic effect of thrombolytic therapy in patients after ischemic stroke with high safety profile. Analysis of the effect of this combination in an increased sample size and a longer follow-up period will be required in the future.

Keywords: Ischemic stroke, Secondary prevention, Cerebroxin capsules, Aspirin